Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial.

Riesterer O, Frank Ciernik I, Stahel RA, Xyrafas A, Aebersold DM, Plasswilm L, Mahmut Ozsahin E, Zwahlen DR, Nackaerts K, Zimmermann F, Sabrina Stark L, Weder W, Krayenbuehl J; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2019 Jun 25;138:121-125. doi: 10.1016/j.radonc.2019.05.024. [Epub ahead of print]

PMID:
31252293
2.

Skin surface markers for stereotactic body radiation therapy of sternal metastasis.

Hemmatazad H, Schmidhalter D, Elicin O, Aebersold DM, Herrmann E.

Rep Pract Oncol Radiother. 2019 Jul-Aug;24(4):322-324. doi: 10.1016/j.rpor.2019.05.005. Epub 2019 May 30.

PMID:
31193944
3.

Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven models.

Poliaková M, Felser A, Pierzchala K, Nuoffer JM, Aebersold DM, Zimmer Y, Zamboni N, Medová M.

FEBS J. 2019 Apr 16. doi: 10.1111/febs.14852. [Epub ahead of print]

PMID:
30993872
4.

Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy.

Shelan M, Odermatt S, Bojaxhiu B, Nguyen DP, Thalmann GN, Aebersold DM, Dal Pra A.

Front Oncol. 2019 Feb 28;9:12. doi: 10.3389/fonc.2019.00012. eCollection 2019.

5.

Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases.

Bachmann N, Leiser D, Ermis E, Vulcu S, Schucht P, Raabe A, Aebersold DM, Herrmann E.

Radiat Oncol. 2019 Mar 14;14(1):45. doi: 10.1186/s13014-019-1252-x.

6.

Whole-ventricular irradiation for intracranial germ cell tumors: Dosimetric comparison of pencil beam scanned protons, intensity-modulated radiotherapy and volumetric-modulated arc therapy.

Correia D, Terribilini D, Zepter S, Pica A, Bizzocchi N, Volken W, Stieb S, Ahlhelm F, Herrmann E, Fix MK, Manser P, Aebersold DM, Weber DC.

Clin Transl Radiat Oncol. 2019 Jan 9;15:53-61. doi: 10.1016/j.ctro.2019.01.002. eCollection 2019 Feb.

7.

Comparison of contemporary staging systems for oropharynx cancer in a surgically treated multi-institutional cohort.

Elicin O, Broglie MA, Fankhauser N, Stoeckli SJ, Pasche P, Reinhard A, Bongiovanni M, Huber GF, Morand GB, Soltermann A, Arnold A, Dettmer MS, Arnoux A, Stauffer E, Espeli V, Martucci F, Aebersold DM, Giger R.

Head Neck. 2019 May;41(5):1395-1402. doi: 10.1002/hed.25574. Epub 2018 Dec 28.

PMID:
30593685
8.

Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.

Orlando E, Aebersold DM, Medová M, Zimmer Y.

Cancer Lett. 2019 Feb 28;443:189-202. doi: 10.1016/j.canlet.2018.12.001. Epub 2018 Dec 11.

PMID:
30550851
9.

Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients.

Elicin O, Sermaxhaj B, Bojaxhiu B, Shelan M, Giger R, Rauch D, Aebersold DM.

Strahlenther Onkol. 2019 Jun;195(6):468-474. doi: 10.1007/s00066-018-1400-5. Epub 2018 Nov 21.

PMID:
30465265
10.

Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.

Bojaxhiu B, Templeton AJ, Elicin O, Shelan M, Zaugg K, Walser M, Giger R, Aebersold DM, Dal Pra A.

Radiat Oncol. 2018 Nov 6;13(1):216. doi: 10.1186/s13014-018-1159-y.

11.

Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.

Nisa L, Barras D, Medová M, Aebersold DM, Medo M, Poliaková M, Koch J, Bojaxhiu B, Eliçin O, Dettmer MS, Angelino P, Giger R, Borner U, Caversaccio MD, Carey TE, Ho L, McKee TA, Delorenzi M, Zimmer Y.

Mol Cancer Res. 2018 Dec;16(12):1912-1926. doi: 10.1158/1541-7786.MCR-18-0056. Epub 2018 Aug 14.

PMID:
30108165
12.

A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).

Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10.

PMID:
30104008
13.

Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy.

Malla B, Aebersold DM, Dal Pra A.

J Transl Med. 2018 Aug 13;16(1):223. doi: 10.1186/s12967-018-1592-6.

14.

Accuracy assessment of a potential clinical use of navigation-guided intra-operative liver metastasis brachytherapy-a planning study.

Herrmann E, Terribilini D, Manser P, Fix MK, Toporek G, Candinas D, Weber S, Aebersold DM, Loessl K.

Strahlenther Onkol. 2018 Nov;194(11):1030-1038. doi: 10.1007/s00066-018-1334-y. Epub 2018 Jul 18.

15.

Part 1: Optimization and evaluation of dynamic trajectory radiotherapy.

Fix MK, Frei D, Volken W, Terribilini D, Mueller S, Elicin O, Hemmatazad H, Aebersold DM, Manser P.

Med Phys. 2018 Jul 10. doi: 10.1002/mp.13086. [Epub ahead of print]

PMID:
29992587
16.

Part 2: Dynamic mixed beam radiotherapy (DYMBER): Photon dynamic trajectories combined with modulated electron beams.

Mueller S, Manser P, Volken W, Frei D, Kueng R, Herrmann E, Elicin O, Aebersold DM, Stampanoni MFM, Fix MK.

Med Phys. 2018 Jul 10. doi: 10.1002/mp.13085. [Epub ahead of print]

PMID:
29992574
17.

Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Glück AA, Orlando E, Leiser D, Poliaková M, Nisa L, Quintin A, Gavini J, Stroka DM, Berezowska S, Bubendorf L, Blaukat A, Aebersold DM, Medová M, Zimmer Y.

Oncogene. 2018 Jul;37(30):4181-4196. doi: 10.1038/s41388-018-0256-6. Epub 2018 May 2.

PMID:
29717265
18.

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.

Poliaková M, Aebersold DM, Zimmer Y, Medová M.

Mol Cancer. 2018 Feb 19;17(1):27. doi: 10.1186/s12943-018-0798-9. Review.

19.

Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.

Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Höcht S, Hölscher T, Sedlmayer F, Wenz F, Zips D, Wiegel T; Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).

Strahlenther Onkol. 2018 Jul;194(7):619-626. doi: 10.1007/s00066-018-1269-3. Epub 2018 Jan 30. Review.

PMID:
29383406
20.

Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.

Cihoric N, Tsikkinis A, Vlaskou Badra E, Glatzer M, Novak U, Scherz A, Shelan M, Soldatovic I, Yojena CKK, Aebersold DM, Lössl K.

Radiat Oncol. 2017 Dec 22;12(1):202. doi: 10.1186/s13014-017-0938-1.

21.

Independent Monte-Carlo dose calculation for MLC based CyberKnife radiotherapy.

Mackeprang PH, Vuong D, Volken W, Henzen D, Schmidhalter D, Malthaner M, Mueller S, Frei D, Stampanoni MFM, Dal Pra A, Aebersold DM, Fix MK, Manser P.

Phys Med Biol. 2017 Dec 19;63(1):015015. doi: 10.1088/1361-6560/aa97f8.

PMID:
29256450
22.

Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10.

Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Stein J, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Dal Pra A, Biaggi Rudolf C, Wust P, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2018 Feb;126(2):257-262. doi: 10.1016/j.radonc.2017.10.025. Epub 2017 Nov 3.

PMID:
29103826
23.

Correction for Aebersold et al., "Extracellular Signal-Regulated Kinase 1c (ERK1c), a Novel 42-Kilodalton ERK, Demonstrates Unique Modes of Regulation, Localization, and Function".

Aebersold DM, Shaul YD, Yung Y, Yarom N, Yao Z, Hanoch T, Seger R.

Mol Cell Biol. 2017 Aug 28;37(18). pii: e00322-17. doi: 10.1128/MCB.00322-17. Print 2017 Sep 15. No abstract available.

24.

Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy.

Malla B, Zaugg K, Vassella E, Aebersold DM, Dal Pra A.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):982-995. doi: 10.1016/j.ijrobp.2017.03.031. Epub 2017 Mar 27. Review.

PMID:
28721912
25.

Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg?

Elicin O, Terribilini D, Shelan M, Volken W, Mathier E, Dal Pra A, Aebersold DM, Fix MK, Manser P.

Radiat Oncol. 2017 Jun 20;12(1):102. doi: 10.1186/s13014-017-0838-4.

26.

Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study.

Herrmann E, Mertineit N, De Bari B, Hoeng L, Caparotti F, Leiser D, Jumeau R, Cihoric N, Jensen AD, Aebersold DM, Ozsahin M.

Radiat Oncol. 2017 Jun 14;12(1):97. doi: 10.1186/s13014-017-0834-8.

27.

Altered regulation of ERK1b by MEK1 and PTP-SL and modified Elk1 phosphorylation by ERK1b are caused by abrogation of the regulatory C-terminal sequence of ERKs.

Yung Y, Yao Z, Aebersold DM, Hanoch T, Seger R.

J Biol Chem. 2017 May 26;292(21):8852. doi: 10.1074/jbc.A117.105995. No abstract available.

28.

Biomechanical Modeling of Pterygium Radiation Surgery: A Retrospective Case Study.

Pajic B, Aebersold DM, Eggspuehler A, Theler FR, Studer HP.

Sensors (Basel). 2017 May 24;17(6). pii: E1200. doi: 10.3390/s17061200.

29.

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.

Nisa L, Häfliger P, Poliaková M, Giger R, Francica P, Aebersold DM, Charles RP, Zimmer Y, Medová M.

Mol Cancer. 2017 May 22;16(1):93. doi: 10.1186/s12943-017-0660-5.

30.

T1-2 glottic cancer treated with radiotherapy and/or surgery.

Shelan M, Anschuetz L, Schubert AD, Bojaxhiu B, Dal Pra A, Behrensmeier F, Aebersold DM, Giger R, Elicin O.

Strahlenther Onkol. 2017 Dec;193(12):995-1004. doi: 10.1007/s00066-017-1139-4. Epub 2017 May 4.

PMID:
28474090
31.

Simultaneous optimization of photons and electrons for mixed beam radiotherapy.

Mueller S, Fix MK, Joosten A, Henzen D, Frei D, Volken W, Kueng R, Aebersold DM, Stampanoni MFM, Manser P.

Phys Med Biol. 2017 Jun 26;62(14):5840-5860. doi: 10.1088/1361-6560/aa70c5.

PMID:
28467321
32.

Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?

Ghadjar P, Hayoz S, Zwahlen DR, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

J Clin Oncol. 2017 May 1;35(13):1490-1491. doi: 10.1200/JCO.2016.70.7265. Epub 2017 Jan 30. No abstract available.

PMID:
28135138
33.

External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26.

Herrmann E, Naehrig D, Sassowsky M, Bigler M, Buijsen J, Ciernik I, Zwahlen D, Pellanda AF, Meister A, Brauchli P, Berardi S, Kuettel E, Dufour JF, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

Radiat Oncol. 2017 Jan 13;12(1):12. doi: 10.1186/s13014-016-0745-0.

34.

In Regard to Pisansky et al.

Ghadjar P, Hayoz S, Zwahlen DR, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK).

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):438-439. doi: 10.1016/j.ijrobp.2016.10.019. No abstract available.

PMID:
28068252
35.

Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov.

Cihoric N, Tsikkinis A, Minniti G, Lagerwaard FJ, Herrlinger U, Mathier E, Soldatovic I, Jeremic B, Ghadjar P, Elicin O, Lössl K, Aebersold DM, Belka C, Herrmann E, Niyazi M.

Radiat Oncol. 2017 Jan 3;12(1):1. doi: 10.1186/s13014-016-0740-5. Review.

36.

Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.

Ghadjar P, Hayoz S, Genitsch V, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Khanfir K, Budach V, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK).

BJU Int. 2017 Nov;120(5B):E45-E51. doi: 10.1111/bju.13742. Epub 2017 Jan 19.

37.

Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.

Francica P, Nisa L, Aebersold DM, Langer R, Bladt F, Blaukat A, Stroka D, Martínez MR, Zimmer Y, Medová M.

Clin Cancer Res. 2016 Nov 1;22(21):5322-5336. Epub 2016 May 16.

38.

Erratum to: Hypofractionated radiotherapy for localized prostate cancer.

Höcht S, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Hölscher T, Martin T, Sedlmayer F, Wenz F, Zips D, Wiegel T.

Strahlenther Onkol. 2016 Nov;192(11):830. No abstract available.

PMID:
27752707
39.

Hypofractionated radiotherapy for localized prostate cancer.

Höcht S, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Hölscher T, Martin T, Sedlmayer F, Wenz F, Zips D, Wiegel T.

Strahlenther Onkol. 2017 Jan;193(1):1-12. doi: 10.1007/s00066-016-1041-5. Epub 2016 Sep 14. Review. Erratum in: Strahlenther Onkol. 2016 Nov;192(11):830.

40.

Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer.

Francica P, Aebersold DM, Medová M.

Biochem Pharmacol. 2017 Feb 15;126:1-12. doi: 10.1016/j.bcp.2016.08.022. Epub 2016 Aug 27. Review.

PMID:
27574725
41.

A mathematical approach to human pterygium shape.

Pajic B, Vastardis I, Rajkovic P, Pajic-Eggspuehler B, Aebersold DM, Cvejic Z.

Clin Ophthalmol. 2016 Jul 22;10:1343-9. doi: 10.2147/OPTH.S106611. eCollection 2016.

42.

Use of a Polylactide-based Copolymer as a Temporary Skin Substitute for a Patient With Moist Desquamation Due to Radiation.

Rothenberger J, Constantinescu MA, Held M, Aebersold DM, Stolz A, Tschumi C, Olariu R.

Wounds. 2016 Jul;28(7):E26-30.

43.

Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).

Ghadjar P, Pöttgen C, Joos D, Hayoz S, Baumann M, Bodis S, Budach W, Studer G, Stromberger C, Zimmermann F, Kaul D, Plasswilm L, Olze H, Bernier J, Wust P, Aebersold DM, Budach V.

Strahlenther Onkol. 2016 Aug;192(8):552-60. doi: 10.1007/s00066-016-0999-3. Epub 2016 Jun 20.

PMID:
27323753
44.

Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis.

Elicin O, Schmucking M, Bromme J, Rauch D, Ambarcioglu P, Plasswilm L, Geretschlager A, Ghadjar P, Giger R, Aebersold DM.

J BUON. 2016 Jan-Feb;21(1):175-81.

45.

Assessing dose rate distributions in VMAT plans.

Mackeprang PH, Volken W, Terribilini D, Frauchiger D, Zaugg K, Aebersold DM, Fix MK, Manser P.

Phys Med Biol. 2016 Apr 21;61(8):3208-21. doi: 10.1088/0031-9155/61/8/3208. Epub 2016 Mar 30.

PMID:
27025897
46.

Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database.

Cihoric N, Tsikkinis A, Miguelez CG, Strnad V, Soldatovic I, Ghadjar P, Jeremic B, Dal Pra A, Aebersold DM, Lössl K.

Radiat Oncol. 2016 Mar 22;11:48. doi: 10.1186/s13014-016-0624-8.

47.

Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes - A systematic review.

Elicin O, Nisa L, Dal Pra A, Bojaxhiu B, Caversaccio M, Schmücking M, Aebersold DM, Giger R.

Radiother Oncol. 2016 May;119(2):185-93. doi: 10.1016/j.radonc.2016.03.003. Epub 2016 Mar 17. Review.

PMID:
26996775
48.

Role of Dose Intensification for Salvage Radiation Therapy after Radical Prostatectomy.

Beck M, Barelkowski T, Kaul D, Wecker S, Thieme AH, Zwahlen DR, Wust P, Aebersold DM, Budach V, Ghadjar P.

Front Oncol. 2016 Mar 1;6:48. doi: 10.3389/fonc.2016.00048. eCollection 2016. Review.

49.

Reply to C. Cozzarini et al.

Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Aebersold DM.

J Clin Oncol. 2016 May 10;34(14):1705-6. doi: 10.1200/JCO.2016.66.7725. Epub 2016 Mar 7. No abstract available.

PMID:
26951315
50.

Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer.

Cihoric N, Tsikkinis A, Tapia C, Aebersold DM, Zlobec I, Lössl K.

Radiat Oncol. 2015 Nov 24;10:240. doi: 10.1186/s13014-015-0551-0.

Supplemental Content

Loading ...
Support Center